Interindividual variability in inhibition and induction of cytochrome P450 enzymes

被引:194
|
作者
Lin, JH [1 ]
Lu, AYH
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
[2] Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08854 USA
关键词
quantitative prediction of drug interactions; intestinal first-pass metabolism; genetic polymorphism; drug interactions;
D O I
10.1146/annurev.pharmtox.41.1.535
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug interactions have always been a major concern in medicine for clinicians and patients. Inhibition and induction of cytochrome P450 (CYP) enzymes are probably the most common causes for documented drug interactions. Today, many pharmaceutical companies are predicting potential interactions of new drug candidates. Can in vivo drug interactions be predicted accurately from in vitro metabolic studies? Should the prediction be qualitative or quantitative? Although some scientists believe that quantitative prediction of drug interactions is possible, others are less optimistic and believe that quantitative prediction would be very difficult. There are many factors that contribute to our inability to quantitatively predict drug interactions. One of the major complicating factors is the large interindividual variability in response to enzyme inhibition and induction. This review examines the sources that are responsible for the interindividual variability in inhibition and induction of cytochrome P450 enzymes.
引用
收藏
页码:535 / 567
页数:33
相关论文
共 50 条
  • [1] Inhibition and induction of human cytochrome P450 (CYP) enzymes
    Pelkonen, O
    Mäenpää, J
    Taavitsainen, P
    Rautio, A
    Raunio, H
    XENOBIOTICA, 1998, 28 (12) : 1203 - 1253
  • [2] Inhibition and induction of human cytochrome P450 enzymes: current status
    Pelkonen, Olavi
    Turpeinen, Miia
    Hakkola, Jukka
    Honkakoski, Paavo
    Hukkanen, Janne
    Raunio, Hannu
    ARCHIVES OF TOXICOLOGY, 2008, 82 (10) : 667 - 715
  • [3] Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin
    Babbar, Sunita
    Chanda, Sanjay
    Bley, Keith
    XENOBIOTICA, 2010, 40 (12) : 807 - 816
  • [4] Inhibition and induction of human cytochrome P450 enzymes: current status
    Olavi Pelkonen
    Miia Turpeinen
    Jukka Hakkola
    Paavo Honkakoski
    Janne Hukkanen
    Hannu Raunio
    Archives of Toxicology, 2008, 82 : 667 - 715
  • [5] Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers
    Ma, JD
    Nafziger, AN
    Bertino, JS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (05): : 447 - 456
  • [6] In Vitro Cytochrome P450 Inhibition and Induction
    Walsky, Robert L.
    Boldt, Sherri E.
    CURRENT DRUG METABOLISM, 2008, 9 (09) : 928 - 939
  • [7] Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes
    Hengstler, J. G.
    Bolt, H. M.
    ARCHIVES OF TOXICOLOGY, 2008, 82 (10) : 665 - 666
  • [8] In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil
    Robertson, P
    Decory, HH
    Madan, A
    Parkinson, A
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (06) : 664 - 671
  • [9] Induction of Phase II enzymes and inhibition of cytochrome P450 isozymes by chitosanoligosaccharides
    Shon, YH
    Nam, KS
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2005, 15 (01) : 183 - 187
  • [10] Induction and inhibition of cytochrome P450 and drug-metabolizing enzymes by climbazole
    Kobayashi, Y
    Suzuki, M
    Ohshiro, N
    Sunagawa, T
    Sasaki, T
    Oguro, T
    Tokuyama, S
    Yamamoto, T
    Yoshida, T
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (01) : 53 - 57